{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:46:49Z","timestamp":1784958409192,"version":"3.55.0"},"reference-count":76,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2017,4,17]],"date-time":"2017-04-17T00:00:00Z","timestamp":1492387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5,9]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Obesity is a very common condition; however, the effect of excess body weight on the appropriate dose of immunoglobulin has not been defined empirically. The proposed pharmacokinetic differences between lean and obese patients and the opportunity to reduce costs has led to the proposition that obese patients should receive proportionally lower doses of immunoglobulin once a certain threshold is reached. Here the theoretical factors which could affect dosing in obese patients are considered alongside the available empirical evidence. The available evidence indicates that obesity may affect the pharmacokinetics of immunoglobulin; however, the effect is likely to be too small to have a clinically important effect on dosing. Wide interpatient individuality and highly variable clinical need mean that obesity should not play a major factor in dosing considerations. However, patients who are obese are more likely to have multiple cardiovascular risk factors and their weight indicates a large dose. This puts these patients at a higher risk of adverse reactions, and therefore caution is advised.<\/jats:p>","DOI":"10.1111\/cei.12955","type":"journal-article","created":{"date-parts":[[2017,3,6]],"date-time":"2017-03-06T16:07:23Z","timestamp":1488816443000},"page":"353-362","source":"Crossref","is-referenced-by-count":34,"title":["Considerations for dosing immunoglobulin in obese patients"],"prefix":"10.1093","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3289-1341","authenticated-orcid":false,"given":"J P","family":"Hodkinson","sequence":"first","affiliation":[{"name":"Corporate Medical Affairs, Biotest AG, Dreieich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,4,17]]},"reference":[{"key":"2021120808030776300_cei12955-bib-0001","volume-title":"Guideline on core SmPC for human normal immunoglobulin for subcutaneous and intramuscular administration","author":"European Medicines Agency (EMA)","year":"2015"},{"key":"2021120808030776300_cei12955-bib-0002","volume-title":"Guideline on core SmPC for human normal immunoglobulin for intravenous administration","author":"European Medicines Agency (EMA)","year":"2010"},{"key":"2021120808030776300_cei12955-bib-0003","first-page":"909","article-title":"Considerations in the use of intravenous immune globulin products","volume":"9","author":"Kasperek","year":"1990","journal-title":"Clin Pharm"},{"key":"2021120808030776300_cei12955-bib-0004","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1177\/106002809302700421","article-title":"Treatment of idiopathic thrombocytopenic purpura using a dose of immunoglobulin based on lean body mass","volume":"27","author":"Woolfrey","year":"1993","journal-title":"Ann Pharmacother"},{"key":"2021120808030776300_cei12955-bib-0005","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/mus.24526","article-title":"Optimizing IgG therapy in chronic autoimmune neuropathies: a hypothesis driven approach","volume":"51","author":"Berger","year":"2015","journal-title":"Muscle Nerve"},{"key":"2021120808030776300_cei12955-bib-0006","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3389\/fimmu.2014.00629","article-title":"Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in Europe","volume":"5","author":"Kerr","year":"2014","journal-title":"Front Immunol"},{"key":"2021120808030776300_cei12955-bib-0007","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1177\/1060028013509789","article-title":"Dosing considerations for obese patients receiving cancer chemotherapeutic agents","volume":"47","author":"Hall","year":"2013","journal-title":"Ann Pharmacother"},{"key":"2021120808030776300_cei12955-bib-0008","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/j.1875-9114.2012.01108.x","article-title":"Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults","volume":"32","author":"Pai","year":"2012","journal-title":"Pharmacotherapy"},{"key":"2021120808030776300_cei12955-bib-0009","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s13181-015-0488-6","article-title":"A review of the toxicologic implications of obesity","volume":"11","author":"Zuckerman","year":"2015","journal-title":"J Med Toxicol"},{"key":"2021120808030776300_cei12955-bib-0010","volume-title":"Global status report on non-communicable diseases 2010","author":"World Health Organization (WHO)","year":"2011"},{"key":"2021120808030776300_cei12955-bib-0011","volume-title":"Prevalence of obesity among adults and youth: United States, 2011\u20132014","author":"Ogden","year":"2015"},{"key":"2021120808030776300_cei12955-bib-0012","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","article-title":"Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies","volume":"363","year":"2004","journal-title":"Lancet"},{"key":"2021120808030776300_cei12955-bib-0013","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2165\/11597140-000000000-00000","article-title":"Current status of body composition assessment in sport: review and position statement on behalf of the ad hoc research working group on body composition health and performance, under the auspices of the I.O.C. Medical Commission","volume":"42","author":"Ackland","year":"2012","journal-title":"Sports Med"},{"key":"2021120808030776300_cei12955-bib-0014","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.jaci.2010.02.040","article-title":"Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years","volume":"125","author":"Lucas","year":"2010","journal-title":"J Allerg Clin Immunol"},{"key":"2021120808030776300_cei12955-bib-0015","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/ACI.0000000000000215","article-title":"Secondary antibody deficiencies","volume":"15","author":"Dhalla","year":"2015","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"2021120808030776300_cei12955-bib-0016","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1146\/annurev-pharmtox-010814-124354","article-title":"Drug disposition in obesity: toward evidence-based dosing","volume":"55","author":"Knibbe","year":"2015","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2021120808030776300_cei12955-bib-0017","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ijantimicag.2016.01.009","article-title":"Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: a structured review","volume":"47","author":"Alobaid","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2021120808030776300_cei12955-bib-0018","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1001\/jamapediatrics.2015.132","article-title":"Drug dosing and pharmacokinetics in children with obesity: a systematic review","volume":"169","author":"Harskamp-van Ginkel","year":"2015","journal-title":"JAMA Pediatr"},{"key":"2021120808030776300_cei12955-bib-0019","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/clpt.2008.170","article-title":"Monoclonal antibody pharmacokinetics and pharmacodynamics","volume":"84","author":"Wang","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"2021120808030776300_cei12955-bib-0020","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1073\/pnas.91.12.5705","article-title":"Macromolecular permeability across the blood\u2013nerve and blood\u2013brain barriers","volume":"91","author":"Poduslo","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021120808030776300_cei12955-bib-0021","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000353293","article-title":"The molecular and biophysical characterization of the human blood\u2013nerve barrier: current concepts","volume":"50","author":"Ubogu","year":"2013","journal-title":"J Vasc Res"},{"key":"2021120808030776300_cei12955-bib-0022","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.clim.2010.05.006","article-title":"Association of FcRn expression with lung abnormalities and IVIG catabolism in patients with common variable immunodeficiency","volume":"136","author":"Freiberger","year":"2010","journal-title":"Clin Immunol"},{"key":"2021120808030776300_cei12955-bib-0023","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40262-012-0027-4","article-title":"Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies","volume":"52","author":"Dostalek","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"2021120808030776300_cei12955-bib-0024","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/sj.clpt.6100381","article-title":"Dosing in obesity: a simple solution to a big problem","volume":"82","author":"Han","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"2021120808030776300_cei12955-bib-0025","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.bpa.2010.12.002","article-title":"Pharmacokinetic considerations in the obese","volume":"25","author":"Leykin","year":"2011","journal-title":"Best Pract Res Clin Anaesthesiol"},{"key":"2021120808030776300_cei12955-bib-0026","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1124\/dmd.111.043604","article-title":"Lymphatic transport and catabolism of therapeutic proteins after subcutaneous administration to rats and dogs","volume":"40","author":"Wang","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"2021120808030776300_cei12955-bib-0027","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pharmthera.2016.03.007","article-title":"A comprehensive review of the neonatal Fc receptor and its application in drug delivery","volume":"161","author":"Martins","year":"2016","journal-title":"Pharmacol Ther"},{"key":"2021120808030776300_cei12955-bib-0028","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/138920021503140412212905","article-title":"Biologics: an update and challenge of their pharmacokinetics","volume":"15","author":"Shi","year":"2014","journal-title":"Curr Drug Metab"},{"key":"2021120808030776300_cei12955-bib-0029","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/intimm\/10.9.1289","article-title":"Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice","volume":"10","author":"Borvak","year":"1998","journal-title":"Int Immunol"},{"issue":"Suppl. 1","key":"2021120808030776300_cei12955-bib-0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000437077","article-title":"The pharmacokinetics of biologics: a primer","volume":"33","author":"Mould","year":"2015","journal-title":"Dig Dis"},{"key":"2021120808030776300_cei12955-bib-0031","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/oby.21003","article-title":"Adipose tissue as an immunological organ","volume":"23","author":"Grant","year":"2015","journal-title":"Obesity (Silver Spring)"},{"key":"2021120808030776300_cei12955-bib-0032","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2147\/ITT.S73223","article-title":"The role of adipokines in chronic inflammation","volume":"5","author":"Mancuso","year":"2016","journal-title":"Immunotargets Ther"},{"issue":"Suppl. 3","key":"2021120808030776300_cei12955-bib-0033","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/dom.12154","article-title":"The immune cells in adipose tissue","volume":"15","author":"Ferrante","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"2021120808030776300_cei12955-bib-0034","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.trsl.2016.07.017","article-title":"Obesity-associated cancer risk: the role of intestinal microbiota in the etiology of the host proinflammatory state","volume":"179","author":"Djuric","year":"2017","journal-title":"Transl Res"},{"key":"2021120808030776300_cei12955-bib-0035","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13073-016-0303-2","article-title":"Impact of the gut microbiota on inflammation, obesity, and metabolic disease","volume":"8","author":"Boulange","year":"2016","journal-title":"Genome Med"},{"key":"2021120808030776300_cei12955-bib-0036","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1038\/sj.ijo.0802496","article-title":"Adipose tissue, insulin action and vascular disease: inflammatory signals","volume":"27","author":"Yudkin","year":"2003","journal-title":"Int J Obes Relat Metab Disord"},{"key":"2021120808030776300_cei12955-bib-0037","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1067\/msy.2003.267","article-title":"Is obesity an inflammatory disease?","volume":"134","author":"Ramos","year":"2003","journal-title":"Surgery"},{"key":"2021120808030776300_cei12955-bib-0038","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"2021120808030776300_cei12955-bib-0039","doi-asserted-by":"crossref","first-page":"R41","DOI":"10.1530\/JOE-13-0516","article-title":"Interplay between the immune system and adipose tissue in obesity","volume":"223","author":"Exley","year":"2014","journal-title":"J Endocrinol"},{"key":"2021120808030776300_cei12955-bib-0040","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.tem.2016.08.004","article-title":"Emerging concepts linking obesity with the hallmarks of cancer","volume":"28","author":"Donohoe","year":"2017","journal-title":"Trends Endocrinol Metab"},{"key":"2021120808030776300_cei12955-bib-0041","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/nm.2002","article-title":"Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters","volume":"15","author":"Feuerer","year":"2009","journal-title":"Nat Med"},{"key":"2021120808030776300_cei12955-bib-0042","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.4049\/jimmunol.1202429","article-title":"Diet-induced obese mice exhibit altered heterologous immunity during a secondary 2009 pandemic H1N1 infection","volume":"191","author":"Milner","year":"2013","journal-title":"J Immunol"},{"key":"2021120808030776300_cei12955-bib-0043","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/jn\/137.5.1236","article-title":"Diet-induced obese mice have increased mortality and altered immune responses when infected with influenza virus","volume":"137","author":"Smith","year":"2007","journal-title":"J Nutr"},{"key":"2021120808030776300_cei12955-bib-0044","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s13054-016-1360-z","article-title":"Increased body mass index and adjusted mortality in ICU patients with sepsis or septic shock: a systematic review and meta-analysis","volume":"20","author":"Pepper","year":"2016","journal-title":"Crit Care"},{"key":"2021120808030776300_cei12955-bib-0045","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1182\/blood-2007-11-124545","article-title":"Common variable immunodeficiency disorders: division into distinct clinical phenotypes","volume":"112","author":"Chapel","year":"2008","journal-title":"Blood"},{"key":"2021120808030776300_cei12955-bib-0046","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11882-016-0597-6","article-title":"Autoimmune and lymphoproliferative complications of common variable immunodeficiency","volume":"16","author":"Maglione","year":"2016","journal-title":"Curr Allergy Asthma Rep"},{"key":"2021120808030776300_cei12955-bib-0047","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1172\/JCI200319246","article-title":"Obesity is associated with macrophage accumulation in adipose tissue","volume":"112","author":"Weisberg","year":"2003","journal-title":"J Clin Investig"},{"key":"2021120808030776300_cei12955-bib-0048","first-page":"530","article-title":"Pharmacokinetic characteristics of therapeutic antibodies","volume":"13","author":"Wohlrab","year":"2015","journal-title":"J Dtsch Dermatol Ges"},{"key":"2021120808030776300_cei12955-bib-0049","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/mus.24554","article-title":"Long-term immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"51","author":"Rajabally","year":"2015","journal-title":"Muscle Nerve"},{"key":"2021120808030776300_cei12955-bib-0050","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/cei.12517","article-title":"Effective dosing strategies for therapeutic immunoglobulin: managing wear-off effects in antibody replacement to immunomodulation","volume":"178","author":"Misbah","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"2021120808030776300_cei12955-bib-0051","first-page":"1657","article-title":"European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology","volume":"30","author":"Enk","year":"2016","journal-title":"J Dtsch Dermatol Ges"},{"key":"2021120808030776300_cei12955-bib-0052","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1007\/s00415-013-6938-7","article-title":"Immunoglobulin G level variations in treated chronic inflammatory demyelinating polyneuropathy: clues for future treatment regimens?","volume":"260","author":"Rajabally","year":"2013","journal-title":"J Neurol"},{"key":"2021120808030776300_cei12955-bib-0053","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jaci.2008.04.044","article-title":"Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection","volume":"122","author":"Bonagura","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"2021120808030776300_cei12955-bib-0054","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.clim.2011.02.020","article-title":"IgG replacement therapy, no size fits all","volume":"139","author":"Bonilla","year":"2011","journal-title":"Clin Immunol"},{"key":"2021120808030776300_cei12955-bib-0055","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S2213-2600(15)00202-7","article-title":"Lung disease in primary antibody deficiency","volume":"3","author":"Verma","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2021120808030776300_cei12955-bib-0056","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/jnnp-2013-306227","article-title":"Pharmacokinetics of intravenous immunoglobulin in multifocal motor neuropathy","volume":"85","author":"Vlam","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021120808030776300_cei12955-bib-0057","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/vox.12275","article-title":"An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency disease","volume":"109","author":"Krivan","year":"2015","journal-title":"Vox Sang"},{"key":"2021120808030776300_cei12955-bib-0058","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/cei.12694","article-title":"Facilitated subcutaneous immunoglobulin (fSCIg) therapy \u2013 practical considerations","volume":"182","author":"Ponsford","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"2021120808030776300_cei12955-bib-0059","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s10875-016-0288-z","article-title":"Switching patients to home-based subcutaneous immunoglobulin: an economic evaluation of an interprofessional drug therapy management program","volume":"36","author":"Perraudin","year":"2016","journal-title":"J Clin Immunol"},{"key":"2021120808030776300_cei12955-bib-0060","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/cei.12099","article-title":"Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency: a retrospective analysis of administration by infusion pump or subcutaneous rapid push","volume":"173","author":"Shapiro","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"2021120808030776300_cei12955-bib-0061","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s40262-015-0361-4","article-title":"Potential sources of inter-subject variability in monoclonal antibody pharmacokinetics","volume":"55","author":"Gill","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"2021120808030776300_cei12955-bib-0062","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2174\/187231211795305302","article-title":"Serum trough IgG level and annual intravenous immunoglobulin dose are not related to body size in patients on regular replacement therapy","volume":"5","author":"Khan","year":"2011","journal-title":"Drug Metab Lett"},{"key":"2021120808030776300_cei12955-bib-0063","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/cei.12616","article-title":"Therapeutic immunoglobulin should be dosed by clinical outcome rather than by body weight in obese patients","volume":"181","author":"Hodkinson","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"2021120808030776300_cei12955-bib-0064","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2146\/ajhp140171","article-title":"Correlation of weight-based i.v. immune globulin doses with changes in serum immunoglobulin G levels","volume":"72","author":"Anderson","year":"2015","journal-title":"Am J Health Syst Pharm"},{"key":"2021120808030776300_cei12955-bib-0065","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/humrep\/der227","article-title":"A two-center study on the pharmacokinetics of intravenous immunoglobulin before and during pregnancy in healthy women with poor obstetrical histories","volume":"26","author":"Ensom","year":"2011","journal-title":"Hum Reprod"},{"key":"2021120808030776300_cei12955-bib-0066","volume-title":"Immunoglobulin database report. London: Department of Health","author":"Medical Data Solutions and Services (MDSAS)","year":"2015"},{"key":"2021120808030776300_cei12955-bib-0067","first-page":"104","article-title":"Protein reference unit handbook","volume-title":"Clinical immunochemistry","author":"Milford","year":"2007","edition":"9th"},{"key":"2021120808030776300_cei12955-bib-0068","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2146\/ajhp110744","article-title":"Impact of ideal body weight dosing for all inpatient i.v. immune globulin indications","volume":"70","author":"Rocchio","year":"2013","journal-title":"Am J Health Syst Pharm"},{"key":"2021120808030776300_cei12955-bib-0069","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1365-2249.2010.04187.x","article-title":"A multi-centre study of efficacy and safety of Intratect(R), a novel intravenous immunoglobulin preparation","volume":"161","author":"Kreuz","year":"2010","journal-title":"Clin Exp Immunol"},{"issue":"Suppl. 1","key":"2021120808030776300_cei12955-bib-0070","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1529-8027.2011.00304.x","article-title":"Serum IgG levels as biomarkers for optimizing IVIg therapy in CIDP","volume":"16","author":"van Doorn","year":"2011","journal-title":"J Peripher Nerv Syst"},{"key":"2021120808030776300_cei12955-bib-0071","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clim.2010.06.012","article-title":"Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies","volume":"137","author":"Orange","year":"2010","journal-title":"Clin Immunol"},{"key":"2021120808030776300_cei12955-bib-0072","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.anai.2013.06.013","article-title":"Optimizing immunoglobulin treatment for patients with primary immunodeficiency disease to prevent pneumonia and infection incidence: review of the current data","volume":"111","author":"Ballow","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2021120808030776300_cei12955-bib-0073","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1007\/s10875-011-9546-2","article-title":"Incidence of infection is inversely related to steady-state (trough) serum IgG level in studies of subcutaneous IgG in PIDD","volume":"31","author":"Berger","year":"2011","journal-title":"J Clin Immunol"},{"key":"2021120808030776300_cei12955-bib-0074","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/cei.12748","article-title":"Clinical and laboratory correlates of lung disease and cancer in adults with idiopathic hypogammaglobulinaemia","volume":"184","author":"Brent","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"2021120808030776300_cei12955-bib-0075","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10875-011-9631-6","article-title":"Higher doses of subcutaneous IgG reduce resource utilization in patients with primary immunodeficiency","volume":"32","author":"Haddad","year":"2012","journal-title":"J Clin Immunol"},{"key":"2021120808030776300_cei12955-bib-0076","first-page":"549","article-title":"Weight-based dosing in medication use: what should we know?","volume":"10","author":"Pan","year":"2016","journal-title":"Patient Prefer Adherence"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcei.12955","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/188\/3\/353\/41642712\/cei12955.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/188\/3\/353\/41642712\/cei12955.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T16:27:50Z","timestamp":1641054470000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/188\/3\/353\/6411952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,17]]},"references-count":76,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,4,17]]},"published-print":{"date-parts":[[2017,5,9]]}},"URL":"https:\/\/doi.org\/10.1111\/cei.12955","relation":{},"ISSN":["1365-2249","0009-9104"],"issn-type":[{"value":"1365-2249","type":"electronic"},{"value":"0009-9104","type":"print"}],"subject":[],"published-other":{"date-parts":[[2017,6]]},"published":{"date-parts":[[2017,4,17]]}}}